[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Kapstahoon BioAndTrade
BioAndTrade posts on X about $srpt, $imrx, $slno, breaker the most. They currently have XXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX +3,059%
- X Months XXXXXX +2,519%
- X Year XXXXXX +511%
Mentions: X #
- X Week XX +47%
- X Month XX +46%
- X Months XX +800%
- X Year XX +371%
Followers: XXX #
- X Week XXX +14%
- X Month XXX +18%
- X Months XXX +26%
- X Year XXX +7%
CreatorRank: undefined #
Social Influence #
Social category influence stocks
Social topic influence $srpt #38, $imrx, $slno, breaker, all the, signals, $qure
Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Soleno Therapeutics, Inc. Common Stock (SLNO) uniQure N.V. (QURE)
Top Social Posts #
Top posts by engagements in the last XX hours
"@rezfszubagoly $SRPT NY medicaid recommends pausing Elevidys. I liked the data which I posted yesterday. It may trigger to other state as well. solid gains from XX so i will wait and see what develops. meanwhile i bought $IMRX and $SLNO"
X Link @Kapstahoon 2025-10-08T20:22Z XXX followers, XXX engagements
"$SRPT it is late breaker presentation by independent investigator"
X Link @Kapstahoon 2025-10-08T05:40Z XXX followers, 1738 engagements
"$SRPT i closed all the my positions. I didnt like the news. I was excited after the data. I had bought mig chunk below 11"
X Link @Kapstahoon 2025-10-08T14:53Z XXX followers, XXX engagements
"$SRPT 3-Year Functional Outcomes of Patients With Duchenne Muscular Dystrophy: Pooled Delandistrogene Moxeparvovec Clinical Trial Data vs External Controls"
X Link @Kapstahoon 2025-10-08T02:35Z XXX followers, 2829 engagements
"@trentkelp $SRPT this is 3-4 years age patient population. X years follow up pooled data posted in a separate post"
X Link @Kapstahoon 2025-10-08T03:11Z XXX followers, XXX engagements
"$SRPT WMS 2025 a) no Treatment related SAEs in 3-4 years old (ambulatory).no new safety signals b) micro-dystrophin expression is higher in 3-4 years old compare to =5 years of age"
X Link @Kapstahoon 2025-10-08T01:57Z XXX followers, 21.3K engagements
"$SRPT recently $qure presented positive safety results recently. They demonstrated that neuro inflammation was reduced when used immunosuppressant along with AMT-130 (gene therapy)"
X Link @Kapstahoon 2025-10-08T05:35Z XXX followers, XXX engagements
"$SRPT good reaction so far overnight tradingkeep in mind that they are also presenting safety when sarilumab used as prophylactic. This is very important data for non-ambulatory patients to reduce ALF. This was one of the key proposal to FDA for non-amb"
X Link @Kapstahoon 2025-10-08T05:35Z XXX followers, XXX engagements